DelveInsight’s ‘COVID-19 Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and COVID-19 Pipeline therapies in various stages of COVID-19 clinical trial development, major pharmaceutical COVID-19 Companies are working to advance the COVID-19 pipeline space and future growth potential of the COVID-19 pipeline domain.
For COVID-19 emerging drugs, the COVID-19 pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The COVID-19 pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
- Over 400+ COVID-19 companies are evaluating 400+ COVID-19 pipeline therapies in various stages of development, and their anticipated acceptance in the COVID-19 market would significantly increase market revenue.
- The leading COVID-19 Companies are developing novel drug candidates to improve the COVID-19 treatment landscape include Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, Inc., Valneva, Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories, UNION Therapeutics, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma, TC BioPharm, Syntax for Science, S.L, SyneuRx, Swedish Orphan Biovitrum, Swedish Herbal Institute AB, Stemedica Cell Technologies, Staidson (Beijing) Biopharmaceuticals Co., Ltd, Sound Pharmaceuticals, Sorrento Therapeutics, SolAeroMed, SK Bioscience, Sinovac Biotech Co., Ltd, Sinocelltech, Shenzhen Kangtai Biological Products Co., Ltd., Shaperon, Senhwa Biosciences, Inc., Selva Therapeutics, Archivel Farma, R-Pharm, Rohto Pharmaceutical, Revimmune, Resverlogix Corporation, Restorbio, Resolve Therapeutics, Renibus Therapeutics, ReiThera, Regeneron Pharmaceuticals, RedHill Biopharma, Red de Terapia Celular, Reata Pharmaceuticals, Inc., Qurient Co, Quercis Pharma, PureTech, Pulmotect, PTC Therapeutics, Pluristem Ltd., Pliant Therapeutics, Pharming Technologies B.V., Pharmenterprises, Pharmamel S.L., Pharma Holdings, Pharco Pharmaceuticals, Pfizer, Petrovax, Paion UK Ltd., Ashvattha Therapeutics, Inc. (Orpheris), OPKO Health, Oncotelic Inc., National Resilience, Inc. (Ology Bioservices), Olatec Therapeutics LLC, Novavax, Novartis Pharmaceuticals, Notitia Biotechnologies Company, Noorik Biopharmaceuticals, Nobelpharma, Moderna, Moderna, MetrioPharm, Merck Sharp & Dohme Corp., Merck KGaA, Medicago Inc., Mallinckrodt, Mabwell (Shanghai) Bioscience Co., Ltd., Lifefactors Zona Franca, Leading BioSciences, Kiniksa Pharmaceuticals, Ltd., 3M, 4D Pharma, AbbVie, Apotex, AgelessRx, AgenTus Therapeutics, AiCuris, AlloVir, Apeiron Biologics, Bausch Health Americas, BeiGene, Biotest, Bio-Thera Solutions, Cadila Healthcare Limited, Cellenkos, Cellularity Incorporated, Chiesi Farmaceutici S.p.A., Clene Nanomedicine, Codagenix, Debiopharm, Direct Biologics, Eiger BioPharmaceuticals, Emergent Biosolutions, Enlivex Therapeutics, Evergreen Therapeutics, Faron Pharmaceuticals, Frontier Biotechnologies, FSD Pharma, Genentech, Inc., Globavir Biosciences, Grand Medical, Grifols Therapeutics LLC, Inotrem, Ionis Pharmaceuticals, Jazz Pharmaceuticals, Kamada, Kiadis Pharma, Medicine Invention, MedRegen LLC, Miltenyi Biomedicine, Natureceuticals Sdn Bhd, NeoImmune Tech, Neutrolis, Ology Bioservices, Oncovir, OPKO Health, Organicell Regenerative Medicine, and others others are evaluating novel drugs for COVID-19 to improve the treatment landscape.
- Promising COVID-19 Pipeline Therapies in various stage of development include XAV-19, Sinapultide, VIR-7831, Maraviroc, Duvelisib, VB 201, AV-001, VLA2001, T3 solution for injection, UNIKINON, UNI911, Umbilical cord derived mesenchymal stem cells, MAD0004J08, Stem Cell Educator therapy, RESP301, TD-0903, TCB008, Bemiparin, Pentarlandir™ UPPTA, Emapalumab, Kan Jang capsules, hMSC, BDB-001, Ebselen, COVI-DROPS| Placebo, STI-5656, COVI-AMG, PSC-04, S-1226, GBP510, SARS-COV-2 inactivated vaccine, SCTA01, SARS-CoV-2 Vaccine (Vero Cells), Inactivated, NuSepin, Silmitasertib, SLV213, RUTI® vaccine, Olokizumab + RPH-104, Mesenchymal stem cell (ADR-001), CYT107, Apabetalone, RTB101, RSLV-132, RBT-9, GRAd-COV2, REGN-COV2 Antibody Cocktail, ABC 294640, Upamostat, Mesenchymal Stromal Cells, Bardoxolone methyl, Telacebec, IQC-950AN, LYT-100, PUL-042, PTC-299, PLX-PAD, PLN-74809, Conestat alfa, Treamid, Melatonin, LTX-109, Selenium, Ramipril, PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, mRNA-1273, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, COVID-19 convalescent plasma, LB1148, Mavrilimumab, and others.
- The COVID-19 Companies and academics are working to assess challenges and seek opportunities that could influence COVID-19 R&D. The COVID-19 pipeline therapies under development are focused on novel approaches to treat/improve COVID-19.
Request a sample and discover the recent breakthroughs happening in COVID-19 pipeline landscape @ COVID-19 Pipeline Outlook Report
Table of Contents
COVID-19 Overview
Coronavirus disease (COVID-19) is an infectious disease caused by the most recently discovered corona virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease causes respiratory illness (like the flu) with symptoms such as a cough, fever, and difficulty breathing. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Elderly people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. The COVID-19 virus is primarily transmitted through droplets of saliva or discharge from the nose when an infected person coughs or sneezes. People can catch COVID-19 if they breathe in droplets from a person with COVID-19 who coughs out or exhales droplets. It also spreads when a person touches a surface or objects that has the virus on it, and then touches their eyes, nose, or mouth.
- REGN-COV2: Regeneron Pharmaceuticals
REGN-COV2 Antibody Cocktail (Casirivimab and Imdevimab; REGN10933 + REGN10987) is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. To develop REGN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company’s VelocImmune® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19. The two potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the virus’s spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population.
- Bucillamine: Revive Therapeutics
Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC.2 The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other antioxidant and anti-inflammatory activity, to lessen the destructive consequences of SARS-CoV2 infection in the lungs and attenuate the clinical course of COVID-19.
- Mupadolimab (CPI-006): Corvus Pharmaceuticals
Mupadolimab (CPI-006) is an antibody that possesses dual properties: binding to CD73, which may reduce its suppression of the immune response via the adenosine pathway; and activating B cells, which may result in increased antibody production to antigens and the generation of memory B cells to extend protection.
Sabizabulin is a cytoskeleton disruptor which by causing microtubule depolymerization has both anti-viral and anti-inflammatory activity and could be effective against the SARS-CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to be transported, replicated, assembled, and released from the cell. In addition, microtubule depolymerization drugs that target the “colchicine binding site” of microtubules, like sabizabulin, also have strong anti-inflammatory effects, including the potential to treat the cytokine release syndrome (cytokine storm) and septic shock induced by the SARS-CoV-2 viral infection that is associated with high COVID-19 mortality rates.
- Sarconeos (BIO101): Biophytis
Sarconeos (BIO101) is an orally administered small molecule in development for the treatment of neuromuscular diseases. Based on results from cellular and animal studies, it is believed that Sarconeos (BIO101) stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility and respiratory capacity in various age-related and muscular wasting conditions.
Leronlimab is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of COVID-19 infection.
- Tocilizumab: Hoffmann-La Roche
Actemra/RoActemra (Tocilizumab) is being developed by Hoffmann-La Roche in phase III stage of development for the treatment of Severe COVID-19 Pneumonia. Actemra/RoActemra is an anti-IL-6 receptor biologic approved to treat moderate-to-severe active rheumatoid arthritis (RA) in adults. The IL-6 protein triggers the body’s immune and inflammatory response to fight infections. But, in the case of those patients where their immune system overreacts, inhibiting IL-6 could keep the body from attacking itself.
In Mar 2020, Roche received Chinese approval for the use of the drug to treat patients developing severe complications from Covid-19.
The new randomized, double-blind, placebo-controlled Phase III trial will be conducted in alliance with the US Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). It will assess the safety and efficacy of Actemra in combination with standard of care compared to placebo.
Find out more about the COVID-19 Diagnosis and Treatment of patients @ COVID-19 Ongoing Clinical Trials Analysis
COVID-19 Key Companies and Pipeline Therapies
- Westvac Biopharma: XAV-19
- Xenothera: Sinapultide
- Windtree Therapeutics: VIR-7831
- Vir Biotechnology: Maraviroc
- ViiV Healthcare: Duvelisib
- Verastem: VB 201
- VBL Therapeutics: AV-001
- Vasomune Therapeutics Inc: VLA2001
- Valneva: UNIKINON
- Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories: UNI911
- UNION Therapeutics: RESP301
- Trustem, Toscana Life Sciences: TD-0903
- Throne Biotechnologies: TCB008
- Thirty respiratory Limited: Bemiparin
- Theravance Biopharma: Emapalumab
- TC BioPharm: Kan Jang capsules
- Syntax for Science SL: hMSC
- Swedish Orphan Biovitrum: BDB-001
- Swedish Herbal Institute AB: Ebselen
- Stemedica Cell Technologies: STI-5656
- Staidson (Beijing) Biopharmaceuticals Co., Ltd: COVI-AMG
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Route of Administration
- Inhalation
- Injection
- Intradermal
- Intramuscular
- Intramuscular/intradermal
- Intranasal
- Intranasal/Intramuscular
- Intranasal/Intravenous
- Intraperitoneal
- Intratracheal
- Intravascular
- Intravenous
- Intravenous/subcutaneous
- Oral
- Oral / Enteral
- Oral and Intravenous
- Oral/nasogastric tube
- Parenteral
- Subcutaneous
- Subcutaneous/Intramuscular
- Subcutaneous/Sublingual
- Sublingual
- Topical
Molecule Type
- Others
- Peptide
- Protein
- Small Molecule
- Stem Cell Therapy
- Vaccine
- Product Type
Discover more about the list of FDA-approved drugs for COVID-19 @ COVID-19 Treatment Landscape
Scope of the COVID-19 Pipeline Report
- Coverage- Global
- COVID-19 Companies: Westvac Biopharma, Xenothera, Windtree Therapeutics (NYSE: WINT), Vir Biotechnology (NYSE: VIR), ViiV Healthcare, Verastem (NYSE: VSTM), VBL Therapeutics (NYSE: VBLT), Vasomune Therapeutics Inc., Valneva (NYSE: VLA), Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories, UNION Therapeutics, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma (NYSE: TBPH), TC BioPharm (NYSE: TCBP), Syntax for Science, S.L, SyneuRx, Swedish Orphan Biovitrum (NYSE: SOBI), Swedish Herbal Institute AB, Stemedica Cell Technologies, Staidson (Beijing) Biopharmaceuticals Co., Ltd, Sound Pharmaceuticals, Sorrento Therapeutics (NYSE: SRNE), SolAeroMed, SK Bioscience, Sinovac Biotech Co., Ltd, Sinocelltech, Shenzhen Kangtai Biological Products Co., Ltd., Shaperon, Senhwa Biosciences Inc., Selva Therapeutics, Archivel Farma, R-Pharm, Rohto Pharmaceutical (NYSE: RPHCF), Revimmune, Resverlogix Corporation (NYSE: RVX), Restorbio, Resolve Therapeutics (NYSE: RLFTF), Renibus Therapeutics, ReiThera, Regeneron Pharmaceuticals (NYSE: REGN), RedHill Biopharma (NYSE: RDHL), Red de Terapia Celular, Reata Pharmaceuticals Inc.(NYSE: RETA), Qurient Co, Quercis Pharma, PureTech (NYSE: PTCHF), Pulmotect, PTC Therapeutics, Pluristem Ltd., Pliant Therapeutics (NYSE: PLRX), Pharming Technologies B.V., Pharmenterprises, Pharmamel S.L., Pharma Holdings, Pharco Pharmaceuticals, Pfizer (NYSE: PFE), Petrovax, Paion UK Ltd., Ashvattha Therapeutics Inc. (Orpheris), OPKO Health, Oncotelic Inc (NYSE: OTLC)., National Resilience, Inc. (Ology Bioservices), Olatec Therapeutics LLC, Novavax, Novartis Pharmaceuticals, Notitia Biotechnologies Company, Noorik Biopharmaceuticals, Nobelpharma, Moderna, Moderna, MetrioPharm, Merck Sharp & Dohme Corp (NYSE: MRK)., Merck KGaA, Medicago Inc., Mallinckrodt, Mabwell (Shanghai) Bioscience Co., Ltd., Lifefactors Zona Franca, Leading BioSciences, Kiniksa Pharmaceuticals (NYSE: KNSA), Ltd., 3M, 4D Pharma, AbbVie (NYSE: ABBV), Apotex, AgelessRx, AgenTus Therapeutics, AiCuris, AlloVir (NYSE: ALVR), Apeiron Biologics, Bausch Health Americas, BeiGene, Biotest, Bio-Thera Solutions, Cadila Healthcare Limited, Cellenkos, Cellularity Incorporated, Chiesi Farmaceutici S.p.A., Clene Nanomedicine, Codagenix, Debiopharm, Direct Biologics, Eiger BioPharmaceuticals, Emergent Biosolutions, Enlivex Therapeutics (NYSE: ENLV), Evergreen Therapeutics, Faron Pharmaceuticals (NYSE: FARN), Frontier Biotechnologies, FSD Pharma, Genentech, Inc., Globavir Biosciences, Grand Medical, Grifols Therapeutics LLC, Inotrem, Ionis Pharmaceuticals (NYSE: IONS), Jazz Pharmaceuticals (NYSE: JAZZ), Kamada, Kiadis Pharma, Medicine Invention, MedRegen LLC, Miltenyi Biomedicine, Natureceuticals Sdn Bhd, NeoImmune Tech, Neutrolis, Ology Bioservices, Oncovir, OPKO Health, Organicell Regenerative Medicine, and others.
- COVID-19 Pipeline Therapies: XAV-19, Sinapultide, VIR-7831, Maraviroc, Duvelisib, VB 201, AV-001, VLA2001, T3 solution for injection, UNIKINON, UNI911, Umbilical cord derived mesenchymal stem cells, MAD0004J08, Stem Cell Educator therapy, RESP301, TD-0903, TCB008, Bemiparin, Pentarlandir™ UPPTA, Emapalumab, Kan Jang capsules, hMSC, BDB-001, Ebselen, COVI-DROPS| Placebo, STI-5656, COVI-AMG, PSC-04, S-1226, GBP510, SARS-COV-2 inactivated vaccine, SCTA01, SARS-CoV-2 Vaccine (Vero Cells), Inactivated, NuSepin, Silmitasertib, SLV213, RUTI® vaccine, Olokizumab + RPH-104, Mesenchymal stem cell (ADR-001), CYT107, Apabetalone, RTB101, RSLV-132, RBT-9, GRAd-COV2, REGN-COV2 Antibody Cocktail, ABC 294640, Upamostat, Mesenchymal Stromal Cells, Bardoxolone methyl, Telacebec, IQC-950AN, LYT-100, PUL-042, PTC-299, PLX-PAD, PLN-74809, Conestat alfa, Treamid, Melatonin, LTX-109, Selenium, Ramipril, PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, mRNA-1273, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, COVID-19 convalescent plasma, LB1148, Mavrilimumab, and others.
- COVID-19 Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type
Dive deep into rich insights for COVID-19 Emerging Therapies and Ongoing Clinical Trials; visit @ COVID-19 Emerging Therapies and Key Players
Table of Content
- Introduction
- COVID-19 Executive Summary
- COVID-19: Overview
- COVID-19 Pipeline Therapeutics
- COVID-19 Pipeline Therapeutic Assessment
- Late Stage Products (Phase III)
- REGN-COV2: Regeneron Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- CNM-ZnAg: Clene Nanomedicine
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- SIR1-365: Sironax
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- SB019: Novan
- Drug profiles in the detailed report…..
- Inactive Products
- COVID-19 Key Companies
- COVID-19 Key Products
- COVID-19- Unmet Needs
- COVID-19- Market Drivers and Barriers
- COVID-19- Future Perspectives and Conclusion
- COVID-19 Analyst Views
- COVID-19 Key Companies
- Appendix
For further information on the COVID-19 Pipeline therapeutics, reach out @ COVID-19 Market Drivers and Barriers
Latest Pharmaceuticals Market Research Reports 2023 by DelveInsight
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market
Latest Blogs by DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
